AIM: To evaluate the therapeutic effect of hydrochlorothiazide in idiopathic renal hypercalciuria. METHODS: We retrospectively analysed the data of 28 children (6.0±4.1 years, M:F=19:9) diagnosed as having idiopathic renal hypercalciuria from the years 1991 to 2008. The dose of hydrochlorothiazide was initially 0.5 mg/kg/day and gradually increased to achieve the appropriate hypocalciuric effect (urinary calcium/creatinine<0.2 mg/mg) in some unresponsive patients. RESULTS: Twenty-two patients (79%) had gross haematuria, 6 (21%) microscopic haematuria, 2 left flank pain, 6 (21%) urolithiasis and 9 (32%) urinary tract infection at the diagnosis of hypercalciuria. The low doses (0.5 mg/kg/day) of hydrochlorothiazide reduced urinary calcium e...
Background. Hydrochlorothiazide (HCT) is applied in the therapy of familial hypomagnesaemia with hyp...
Abstract Background Nephrolithiasis is a global healthcare problem with a current lifetime risk of 1...
Nephrolithiasis is a global healthcare problem with a current lifetime risk of 18.8% in men and 9.4%...
There is a growing recognition that children with Lowe syndrome are at risk of nephrocalcinosis and ...
There is a growing recognition that children with Lowe syndrome are at risk of nephrocalcinosis and ...
There is a growing recognition that children with Lowe syndrome are at risk of nephrocalcinosis and ...
BACKGROUND: Hydrochlorothiazide (HCT) is applied in the therapy of familial hypomagnesaemia with hyp...
Objective: Idiopathic hypercalciuria (IH) is a metabolic risk factor in patients with urinary calciu...
We report 5 years' experience with low-dose hydrochlorothiazide, 50 mg/day and amiloride, 5 mg/day, ...
In 1962, we began a clinical trial designed to assess the efficacy of the thiazide diuretics in the ...
Thiazide-type diuretics are commonly used in the treatment of hypertension and nephrolithiasis. Evid...
Background. Hydrochlorothiazide (HCT) is applied in the therapy of familial hypomagnesaemia with hyp...
1. Since prostaglandin E2 could play a role in idiopathic hypercalciuria, and considering the well-e...
1. Since prostaglandin E2 could play a role in idiopathic hypercalciuria, and considering the well-e...
1. Since prostaglandin E2 could play a role in idiopathic hypercalciuria, and considering the well-e...
Background. Hydrochlorothiazide (HCT) is applied in the therapy of familial hypomagnesaemia with hyp...
Abstract Background Nephrolithiasis is a global healthcare problem with a current lifetime risk of 1...
Nephrolithiasis is a global healthcare problem with a current lifetime risk of 18.8% in men and 9.4%...
There is a growing recognition that children with Lowe syndrome are at risk of nephrocalcinosis and ...
There is a growing recognition that children with Lowe syndrome are at risk of nephrocalcinosis and ...
There is a growing recognition that children with Lowe syndrome are at risk of nephrocalcinosis and ...
BACKGROUND: Hydrochlorothiazide (HCT) is applied in the therapy of familial hypomagnesaemia with hyp...
Objective: Idiopathic hypercalciuria (IH) is a metabolic risk factor in patients with urinary calciu...
We report 5 years' experience with low-dose hydrochlorothiazide, 50 mg/day and amiloride, 5 mg/day, ...
In 1962, we began a clinical trial designed to assess the efficacy of the thiazide diuretics in the ...
Thiazide-type diuretics are commonly used in the treatment of hypertension and nephrolithiasis. Evid...
Background. Hydrochlorothiazide (HCT) is applied in the therapy of familial hypomagnesaemia with hyp...
1. Since prostaglandin E2 could play a role in idiopathic hypercalciuria, and considering the well-e...
1. Since prostaglandin E2 could play a role in idiopathic hypercalciuria, and considering the well-e...
1. Since prostaglandin E2 could play a role in idiopathic hypercalciuria, and considering the well-e...
Background. Hydrochlorothiazide (HCT) is applied in the therapy of familial hypomagnesaemia with hyp...
Abstract Background Nephrolithiasis is a global healthcare problem with a current lifetime risk of 1...
Nephrolithiasis is a global healthcare problem with a current lifetime risk of 18.8% in men and 9.4%...